Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min

A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or nevirapine was conducted to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Lisa L., Walker, A. Sarah, Lou, Yu, Tenorio, Allan R., Gibb, Diana M., Double, Julia, Gilks, Charles, McCoig, Cynthia C., Munderi, Paula, Musoro, Godfrey, Kityo, Cissy M., Grosskurth, Heiner, Hakim, James, Mugyenyi, Peter N., Cutrell, Amy, Perger, Teodora, Shaefer, Mark S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855468/
https://www.ncbi.nlm.nih.gov/pubmed/31725787
http://dx.doi.org/10.1371/journal.pone.0225199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855468/
https://www.ncbi.nlm.nih.gov/pubmed/31725787
http://dx.doi.org/10.1371/journal.pone.0225199

Ejemplares similares